5-HT4 Receptor Agonist Use for Menopause-Linked Cognitive Decline
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is no effective treatment available for dementia due to menopause, cognitive deficits of schizophrenia, or chemotherapy-induced cognitive impairment, which cause significant cognitive decline and quality of life issues in affected individuals.
Innovation Solution
The use of Isopropyl-3-{5-[1-(3-methoxypropyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole or its pharmaceutically acceptable salts as a 5-HT4 receptor agonist to enhance cognitive function and reverse memory deficits in animal models of menopause, schizophrenia, and chemotherapy-induced impairment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If hormone replacement therapy is used to treat menopausal symptoms, then physiological changes and disabilities are improved, but risk of uterine, ovarian and breast cancers, pulmonary embolism, cardiac disease and stroke increases
Solution Approach 1:
The patent introduces 5-HT4 receptor agonists as an intermediary substance that acts on the serotonin receptors in the brain to improve cognitive function during menopause, bypassing the need for direct hormone replacement and its associated risks. The compound modulates neurotransmitter activity rather than replacing hormones, thus achieving therapeutic effect without the harmful side effects of HRT.
Solution Approach 2:
The patent changes the therapeutic approach from hormonal parameter modification to neurotransmitter parameter modification. By targeting 5-HT4 receptors and modulating serotonin activity, the invention achieves cognitive improvement without altering hormone levels, thereby avoiding the cancer and cardiovascular risks associated with hormonal therapy.
2Object-affected harmful factors
If cholinesterase inhibitors are used to treat cognitive decline in menopause, then cognitive function is improved, but no alternative effective therapy is approved and side effects occur
Solution Approach 1:
The patent uses 5-HT4 receptor agonists as an intermediary mechanism that acts on serotonin receptors to improve cognitive function, providing an alternative to cholinesterase inhibitors. This approach targets a different neurotransmitter system (serotonin vs. acetylcholine), offering a new therapeutic pathway with potentially better safety profile.
3Reliability
If chemotherapy is used to treat cancer, then cancer survival rates are improved, but cognitive impairment and chemobrain symptoms occur
Solution Approach 1:
The patent identifies 5-HT4 receptor agonists as a therapeutic intervention that can convert the harmful cognitive effects of chemotherapy into beneficial outcomes. By activating 5-HT4 receptors, the compound may protect against chemobrain symptoms and cognitive impairment, turning a harmful side effect into a treatable condition with potential neuroprotective benefits.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The 5-HT4 receptor agonist significantly improves memory and cognitive functions in animal models of menopause, schizophrenia, and chemotherapy-induced cognitive impairment, indicating its potential as a therapeutic candidate for these conditions.
Implementation Method 1
The 5-HT 4 receptors are highly expressed in brain regions like hippocampus, amygdala and cerebral cortex suggesting the involvement of receptor in cognitive processes
Implementation Method 2
Stimulation of 5-HT 4 receptors increases extracellular histamine and acetylcholine levels in rodents in these brain regions involved in cognitive function
Implementation Method 3
The sAPPα is non-amyloidogenic protein and it is reported to have potent neuroprotective role against neurotoxic effects of glutamate and β-amyloid
Implementation Method 4
The 5-HT 4 receptor agonists modulate amyloid precursor protein (APP) derived peptides, amyloid beta (Aβ) and soluble amyloid precursor protein alpha (sAPPα)
Data Source
Figure 1~2
Figure 3
AI summary
The present invention relates to new uses of a 5-HT4 receptor agonist, specifically Isopropyl-3 - { 5- [ 1 -(3 -methoxypropyl) piperidin-4-yl] - [ 1,3,4] oxadiazol-2-yl } - 1 H- indazole (Compound- 1) or a pharmaceutically acceptable salts thereof, for the treatment of dementia due to menopause, senile dementia, cognitive deficits associated with schizophrenia, depression, chemotherapy-induced cognitive impairment, and behavioral and psychological symptoms of dementia such as apathy/indifference, agitation, aggression, depression, anxiety, irritability/lability, dysphoria, aberrant motor behavior, delusions, hallucinations, elation/euphoria, psychosis, disinhibition, sleep and night time behavior disorders or appetite and eating disorders. The present invention further provides use of the said compounds in the manufacture of medicament intended for the treatment of the disorders described herein.